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Introduction
Alpha-1-acid glycoprotein (α 1 -AGP) is an important glycoprotein found in the plasma. It has a molecular weight of 41-43 kDa and comprises a single chain of 183 amino acids, with five N-linked oligosaccharides (glycans). 1 The carbohydrate content makes up 45% of the protein's total molecular weight. It is an acute-phase protein and the blood plasma concentration of the protein increases in response to inflammation. α 1 -AGP has a normal plasma concentration between 0.6-1.2 mg/mL, representing 1-3% of the total blood plasma protein concentration. Following an acute phase reaction (e.g. stress, inflammation, burn or infection), the α 1 -AGP concentration in blood can increase up to 400% from its normal concentration.
It exists as a mixture of two or three genetic variants. 1 Two genetic polymorphs are the A and the major (70%) F 1 S variants; in the A variant, 22 amino acids out of 183 residues differ from the F 1 S polymorph. The differences in structure of the polymorphs translate into slightly different drug binding properties. For example, α 1 -AGP has an isoelectric point (pI) of 2.7-3.0, and predominantly binds to neutral and basic drugs [2] [3] [4] [5] such as methadone, 2 chlorpromazine and disopyramide. 3, 4 A wide range of drugs is known to bind to α 1 -AGP. Large g em values characterize the chiroptical behavior of these complexes, with g em being described by equation 1.
The long-lifetime of the luminescence allows the lanthanide complex to be observed selectively using time-gating. The emissive state of the lanthanide is also highly sensitive to the coordination environment of the complex, so changes due to 
Results and Discussion
The competitive binding of selected drugs (Figure 1 ) to the pre-formed complex,
[Eu.L 1 .AGP], was monitored by studying the spectral changes in the total and CPL emission. Each titration was set up and carried out in the same manner. The free complex (30 µM) was dissolved in aqueous NaCl solution (1 mL, 0.1 M) and α 1 -AGP was added to the solution to give a 1:1 (complex:AGP) ratio. The pH was adjusted to 7.4 and initial emission and CPL spectrum were acquired. Incremental additions of the drug were made, maintaining the pH at 7.4 (I = 0.1 NaCl; 295K). Each titration was halted after ten equivalents of the drug had been added ([drug] = 300 µM) and the final emission and CPL spectra were recorded. The total emission intensity reduced in magnitude and the significant changes in spectral form permitted ratiometric analysis to be undertaken, measuring the change in the ΔJ =2/ΔJ =1 intensity ratio as a function of the concentration of added drug, ( Table 1) . Parallel experiments were attempted with the terbium analogue, 14 but the protein-bound complex was significantly more quenched by charge transfer, and the less strong observed emission signal -in both CPL and total emission-precluded detailed quantitative studies. Overall, the most significant changes occurred in the hypersensitive ΔJ = 2 and ΔJ = 4 manifolds. In parallel, the reduction in the CPL emission intensity at 621 nm was plotted as a function of drug concentration. (Figures 1-3 ; Table 1 and SI). The CPL intensity variation was also assessed at 613 nm and gave near identical data, within the estimated error. Binding isotherms derived from CPL and total emission data were analysed assuming a 1:1 binding stoichiometry for the interaction of the drug at the major AGP binding site; such a stoichiometry is consistent with literature precedent. The binding of the drug to α 1 -AGP first involves the dissociation of the complex from the protein binding site, followed by association of the drug into the binding pocket.
The europium CPL and total emission changes provide information on the first Each titration was repeated twice and an average value is given. The main source of error in the CPL experimental data can be traced to the CPL detector response, in which the signal is only reliable when it is five times larger than the background noise. However, the quoted error on the binding constants derives from the fitting function, and so is an underestimate of the true error. 
Summary
Drug binding to a protein has been studied quantitatively for the first time, using changes in circularly polarized luminescence. For the series of anaesthetics, lidocaine bound most weakly, and there was evidence from the total emission behaviour that Sbupivacaine bound more strongly than the racemate. Levobupivacaine is the (S)-enantiomer of bupivacaine and a similar apparent binding constant to native AGP was calculated in each case, although the literature binding constant to AGP is reported to be slightly higher for racemic bupivacaine than for the S enantiomer (log K = 5.72 vs 5.43). 10b,10c However, another study has suggested that S-bupivacaine has a higher affinity towards the F 1 S variant of AGP than racemic bupivacaine, with logK values of 5.84 (± 0.02) and 5.52 (± 0.03) respectively. The F 1 S variant normally constitutes 70% of the total AGP, and so usually is the more important to consider. 14 Therefore, some caution needs to exercised in interpreting these data. 10a Of the remaining systems analysed, imipramine bound more strongly than the related nortriptyline, whilst the more hydrophobic imatinib, bound most strongly, in accord with literature binding data.
Conclusions
The competitive binding to α 1 -acid glycoprotein of the selected pharmacologically active compounds can be assessed quickly and easily by observing the total emission and CPL spectral changes of the chiral Eu(III) complex, [Eu.
is important for dosage and treatment protocols, as the fraction of free and bound drug in vivo will depend on the concentration of AGP in serum, and this varies in a variety of disease states, notably in infection and inflammation. Given that related Eu(III)
complexes have been used to monitor analytes like citrate, lactate and urate 16 in a wide range of bio-fluids, using relatively cheap instrumentation, such sensitive luminescence methods offer scope for development. Moreover, alpha-1-acid glycoprotein itself has been identified, following a study on17,345 patients, as one of only four key circulating 'biomarkers', that can be used to estimate the five-year risk of "all-cause" mortality. Indeed, α 1 -AGP was stated to be 'the strongest multivariate predictor of the risk of death from all causes'. The other three biomarkers are citrate, albumin and the particle size of very low density lipoprotein. Table 2 ). The UV detector was set at 336 nm and fraction collection was performed manually. Step Elmer LS55 spectrometer using custom written software. The Ln 3+ ion was directly excited via the chromophore using a short pulse of light at λ exc (336 nm for [Eu.L 1 (OH 2 )] + ) , followed by monitoring the integrated intensity of the light emitted at a chosen wavelength (612.5 nm for Eu), during a fixed gate time, t g , after a delay time, t d . Measurements were made for a minimum of 20 delay times, covering more than 3 lifetimes. A gate time of 0.1 ms was used and the excitation and emission slits were set to 10 nm. The observed decay curves were plotted in Excel using eq. 1.
The excited state lifetime, τ, is the inverse of the radiative decay rate constant, k.
Apparent binding constants were calculated by fitting equation 2 to emission or CPL data using Origin TM software and non-linear least squares regression analysis. The CPL spectra were recorded on a custom built spectrometer 15 consisting of a laser driven light source (Energetiq EQ-99 LDLS, spectral range 170 to 2100 nm) coupled to an Acton SP2150 monochromator (600 g/nm, 300 nm Blaze) that allows excitation wavelengths to be selected with a 6 nm FWHM band-pass. The collection of the emitted light was facilitated (90° angle set up, 1 cm path length quartz cuvette) by a Lock-In Amplifier (Hinds Instruments Signaloc 2100) and Photoelastic Modulator (Hinds Instruments PEM-90). The differentiated light was focused onto an Acton SP2150 monochromator (1200 g/nm, 500 nm Blaze) equipped with a high sensitivity cooled Photo Multiplier Tube (Hamamatsu 10723-01 red corrected).
The detection of the CPL signal was achieved using the field modulation lock-in technique. The electronic signal from the PMT was fed into the lock-in amplifier (Hinds Instruments Signaloc 2100). The reference signal for the lock-in detection was provided by the PEM control unit. The monochromators, PEM control unit and lockin amplifier were interfaced with a desktop PC and controlled by Labview code.
A correction factor for the wavelength dependence of the detection system was constructed using a calibrated lamp (Edmund Optics). The measured raw data was subsequently corrected using this correction factor. The validation of the CPL detection systems was achieved using light emitting diodes (LEDs) at various emission wavelengths. The LED was mounted in the sample holder and the light from the LED (650 nm) was fed through a broad-band polarising filter and quarter wave plate (Thor Labs) to generate circularly polarised light. Prior to all measurements, this technique was used to set the phase of the lock-in amplifier correctly. Spectra were recorded using a 5 spectral average sequence in the range of 570-720 nm (Eu), with 0.5 nm spectral intervals and using a 500 microsecond integration time.
